Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EARLY BOT-SPAS: Early Botulinum Toxin in First Stroke Patients
NCT06811142Phase 1Not yet recruiting
- Sponsor
- Instituto Mexicano del Seguro Social
- Start
- Dec 2026
- Primary completion
- Feb 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1 trial of botulinum toxin type A in spasticity (2 arms), sponsored by Instituto Mexicano del Seguro Social. Primary endpoints: Modified Ashworth Scale at 12 months and Modified Tardieu Scale at 12 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
spasticity
Beyond the preview
Go deeper on NCT06811142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06811142.